Contact this trialFirst, we need to learn more about you.
Cancer Vaccine
GO-203-2C for Acute Myeloid Leukemia
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is testing a new targeted therapy for AML patients. The therapy, GO-203-2C, is being tested both alone and in combination with decitabine. This is a Phase I/II clinical trial, which means they are testing both the safety and effectiveness of the new therapy.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service